In situ hybridization techniques involve the detection of specific nucleic acid sequences (DNA or RNA) inside the cells, using specific probes marked.
EBER probe is used for the identification of latent infection caused by the Epstein-Barr virus (EBV) associated with several diseases, such as: Hodgkin's lymphoma, B cell lymphoma, nasopharyngeal carcinoma, gastric carcinoma and others.
Kappa and Lambda probes are used for identification of mRNA from Kappa and Lambda light chains from the immunoglobulins of B cells.
The HER2 gene is amplified and over-expressed in invasive forms of breast cancer, uterine cancer, ovarian cancer, endometrial cancer, gastric cancer, prostate cancer and osteosarcoma. It represents a predictive factor of the therapeutic efficacy with the monoclonal antibody Trastuzumab (Herceptin).
|Chromogenic in situ hybridization (CISH)
|ALU Positive Control Probe II
Description of the technique
EBER, Kappa and Lambda probes are labeled with fluorescein and used with the Vision Biosystems automated system (Bond) with DAB chromogenic visualization.
HER2 CISH Kit is a two-color signal chromogenic visualization, obtained with specific probes for the HER2 gene (red signal) and the centromeric region of chromosome 17 (blue signal). It uses a mixture of DNA probes labeled with Texas red for the HER2 gene, and a mixture of fluorescein-labeled PNA probes for the centromeric region of chromosome 17 (CEN-17).
In the SISH method, the HER2 gene is detected by hybridization with a labeled DNA probe with Dinitrophenol (DNP) and visualization with silver, followed by hybridization with the centromere CEN17 probe, labeled with DNP and visualization with Fast Red.